Baroda BNP Paribas Health and Wellness Fund
Direct · GrowthAI Summary
The fund delivered a 1Y SIP XIRR of 19.10%, comfortably ahead of the category average of 14.10% for the same period. Against the NIFTY 50, it posted a 1Y CAGR of 10.83% versus the benchmark's -2.90%, generating a strong alpha of 9.20%. However, longer-term lump-sum CAGRs are modest, with 5Y at 1.82% and alpha turning negative (-0.67%) over that horizon.
The fund exhibits low beta of roughly 0.52-0.53 across horizons, with downside capture of 43-45% versus upside capture of 58-60%, indicating it has fallen far less than the benchmark in weak markets. It recorded only one drawdown event exceeding 10%, with a maximum drawdown of just -0.11% that took 110 days to recover. The 1Y Calmar ratio of 0.75 reflects reasonable risk-adjusted performance relative to its drawdown profile.
The portfolio is heavily concentrated in Pharmaceuticals & Biotechnology at 72.1% of assets, with Healthcare Services adding another 19.7%, leaving minimal exposure elsewhere. Sun Pharma (8.82%) and Torrent Pharma (8.58%) are the top holdings, and the top 10 positions account for roughly 59% of NAV across 30 total holdings. This deep sector focus is typical of a thematic healthcare fund but offers little diversification beyond the sector.
On the primary SIP metric, the fund's 1Y XIRR of 19.10% outpaces the category average of 14.10%, showing strong recent relative performance. Longer-horizon comparisons are less favorable, as lump-sum CAGRs of 0.6-3.1% over 3Y-15Y periods trail the category's SIP XIRR averages of 16-17%, though these metrics are not directly comparable. The negative alpha beyond 3 years suggests the fund has struggled to beat the broad benchmark over extended holding periods.
This fund suits investors with high risk tolerance who want a tactical, sector-specific allocation to healthcare and pharmaceuticals alongside a diversified core portfolio. A long time horizon of 5-7 years or more is advisable given the sector's cyclicality and the fund's weak long-term lump-sum returns. It should be treated as a satellite holding, sized modestly, rather than a core equity investment.
- 1Y SIP XIRR of 19.10% exceeds the category average of 14.10% by a wide margin
- Low beta of 0.52 with downside capture of 43-45% provides meaningful cushioning in falling markets
- Strong 1Y alpha of 9.20% versus the NIFTY 50, which declined 2.90% over the same period
- Extreme sector concentration, with Pharmaceuticals & Biotechnology at 72.1% and Healthcare Services at 19.7%, exposes investors to single-sector risk
- Negative alpha over 5Y-15Y horizons (-0.67% to -2.26%) indicates long-term underperformance versus the benchmark
- Only 1Y XIRR data is available, limiting the ability to assess consistency of SIP returns across market cycles
Generated on 05-09-2026, 3:04 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹13.13 L | 19.1% | 6.9% | 28.4% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 19.1% | 14.4% | 14.1% | +4.7% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 8.3% | 7.4% | 4.0% | 13.7% | 0.68 | 2.84 | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +9.20 | 0.52 | 58.6% | 43.1% | 10.8% | -2.9% |
| 3 Years | +0.94 | 0.53 | 60.3% | 45.3% | 3.1% | -1.7% |
| 5 Years | -0.67 | 0.53 | 60.3% | 45.3% | 1.8% | -1.0% |
| 7 Years | -1.34 | 0.53 | 60.3% | 45.3% | 1.3% | -0.8% |
| 10 Years | -1.85 | 0.53 | 60.3% | 45.3% | 0.9% | -0.5% |
| 12 Years | -2.05 | 0.53 | 60.3% | 45.3% | 0.8% | -0.4% |
| 15 Years | -2.26 | 0.53 | 60.3% | 45.3% | 0.6% | -0.3% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited | 8.82% |
| 2 | Torrent Pharmaceuticals Limited | 8.58% |
| 3 | Divi's Laboratories Limited | 6.66% |
| 4 | Lupin Limited | 6.46% |
| 5 | IPCA Laboratories Limited | 5.72% |
| 6 | Apollo Hospitals Enterprise Limited | 5.35% |
| 7 | Laurus Labs Limited | 5.24% |
| 8 | Fortis Healthcare Limited | 4.55% |
| 9 | AstraZeneca Pharma India Limited | 4.05% |
| 10 | Glenmark Pharmaceuticals Limited | 3.44% |